Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





CYCLOPENTANE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 287-92-3; **Chemical Formula:** CH2CH2CH2CH2CH2
Previously, OSHA had no limit for cyclopentane. The proposed PEL was 600 ppm as an 8-hour TWA, and NIOSH concurred with this limit (Ex. 8-47, Table N1). The final rule promulgates this limit, which is consistent with that of the ACGIH. Cyclopentane is a mobile, colorless, and flammable liquid.
The existing animal data indicate that cyclopentane is a narcotic agent. As with other alicyclic hydrocarbons, exposure to high concentrations causes excitement, loss of equilibrium, stupor, coma, and, rarely, respiratory failure (Gerarde 1963a, as cited in ACGIH 1986/Ex. 1-3, p. 164). No major animal studies on the effects of cyclopentane exposure have been reported, and evaluations of the toxic properties of this substance have therefore relied on the animal data for n-pentane. n-Pentane has been shown to cause narcosis in animals at exposures of 90,000 to 120,000 ppm for 5 to 60 minutes (Abbritti, Siracusa, Cianchetti et al. 1976/ Ex. 1-406). Swann, Kwon, and Hogan (1974/Ex. 1-124) reported that a concentration of 130,000 ppm is fatal. Almost no data are available concerning the chronic effects of cyclopentane exposure. Abbritti, Siracusa, Cianchetti et al. (1976/Ex. 1-406) reported that petroleum solvents used in the Italian shoe industry contain up to 18 percent cyclopentane. Workers exposed to these solvents have developed polyneuropathy, and Oettel (1936/Ex. 1-921) reported that skin exposure to such solvents caused burning and skin blistering after 15 minutes of confined contact. It has not been determined whether the irritation was caused by cyclopentane or by cyclopentane and other substances, such as n-hexane, in the solvent. OSHA received no comments other than those from NIOSH.
In the final rule, OSHA is establishing a PEL of 600 ppm as an 8-hour TWA for cyclopentane. OSHA concludes that occupational exposure to cyclopentane poses a significant risk of irritation and narcosis, which constitute material impairments of health that occur at levels somewhat above the PEL established in the final rule.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue